| Year |
Citation |
Score |
| 2019 |
Wasmann RE, Smit C, van Dongen EPH, Wiezer RMJ, Adler-Moore J, de Beer YM, Burger DM, Knibbe CAJ, Brüggemann RJM. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31588493 DOI: 10.1093/Cid/Ciz885 |
0.301 |
|
| 2019 |
Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 68: S244-S259. PMID 31222254 DOI: 10.1093/Cid/Ciz064 |
0.389 |
|
| 2019 |
Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 68: S260-S274. PMID 31222253 DOI: 10.1093/Cid/Ciz076 |
0.343 |
|
| 2019 |
Walsh TJ, Lewis RE, Adler-Moore J. Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 68: S241-S243. PMID 31222252 DOI: 10.1093/Cid/Ciz091 |
0.374 |
|
| 2019 |
Dave JJ, Sandoval A, Olson J, Adler-Moore J. 1577. Particle Characterization of Nebulized Liposomal Amphotericin B and Its Use in the Treatment of Murine Pulmonary Aspergillosis Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz360.1441 |
0.355 |
|
| 2019 |
Sandoval A, Adler-Moore J. 1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis Open Forum Infectious Diseases. 6. DOI: 10.1093/Ofid/Ofz360.1418 |
0.395 |
|
| 2018 |
Olson J, Slarve M, Adler-Moore J. 1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains Open Forum Infectious Diseases. 5. DOI: 10.1093/Ofid/Ofy209.109 |
0.38 |
|
| 2016 |
Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Medical Mycology. 54: 223-31. PMID 26768369 DOI: 10.1093/mmy/myv111 |
0.301 |
|
| 2007 |
Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. The Journal of Antimicrobial Chemotherapy. 59: 941-51. PMID 17400589 DOI: 10.1093/jac/dkm077 |
0.34 |
|
| 2006 |
Spellberg B, Schwartz J, Fu Y, Avanesian V, Adler-Moore J, Edwards JE, Ibrahim AS. Comparison of antifungal treatments for murine fusariosis. The Journal of Antimicrobial Chemotherapy. 58: 973-9. PMID 16973654 DOI: 10.1093/Jac/Dkl378 |
0.34 |
|
| 2006 |
Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 43: 917-24. PMID 16941377 DOI: 10.1086/507530 |
0.423 |
|
| 2006 |
Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrobial Agents and Chemotherapy. 50: 2122-31. PMID 16723574 DOI: 10.1128/AAC.00315-06 |
0.307 |
|
| 2005 |
Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrobial Agents and Chemotherapy. 49: 4895-902. PMID 16304150 DOI: 10.1128/AAC.49.12.4895-4902.2005 |
0.316 |
|
| 2003 |
Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Current Opinion in Investigational Drugs (London, England : 2000). 4: 179-85. PMID 12669379 |
0.308 |
|
| 2002 |
Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. The Journal of Antimicrobial Chemotherapy. 49: 21-30. PMID 11801577 DOI: 10.1093/Jac/49.Suppl_1.21 |
0.452 |
|
| 2001 |
Dhillon J, Fielding R, Adler-Moore J, Goodall RL, Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis Journal of Antimicrobial Chemotherapy. 48: 869-876. PMID 11733471 DOI: 10.1093/Jac/48.6.869 |
0.33 |
|
| Show low-probability matches. |